Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness

NATerminatedINTERVENTIONAL
Enrollment

396

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

January 4, 2022

Study Completion Date

January 4, 2022

Conditions
COVID-19 Convalescent Plasma Treatment
Interventions
BIOLOGICAL

COVID-19 convalescent plasma treatment

"The donor's blood will be collected after four weeks post-onset of illness. 600 ml ABO-compatible plasma sample will be harvested during apheresis from each donor and each sample will be divided and stored as 200 mL aliquots.~Patients who meet the criteria receive one dose (200 mL) of ABO compatible inactivated convalescent plasma with a confirmed neutralization activity."

Trial Locations (1)

50-556

Wroclaw Medical University, Wroclaw

Sponsors
All Listed Sponsors
collaborator

Medical Research Agency, Poland

OTHER_GOV

lead

Wroclaw Medical University

OTHER

NCT04642014 - Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness | Biotech Hunter | Biotech Hunter